Background Hypertrophic cardiomyopathy (HCM) is a leading cause of sudden cardiac death (SCD) among young individuals and ...
Background Dyspnoea and reduced exercise capacity are common features in hypertrophic cardiomyopathy (HCM) without left ...
Cytokinetics, Incorporated awaits a pivotal FDA decision on aficamten for hypertrophic cardiomyopathy, with the PDUFA date set for December 26th. Aficamten has shown strong clinical results and safety ...
Thank you, everyone, for tuning in. I'm Andrew Tsai, Senior biotech analyst at Jefferies, and it's my pleasure to have the Lexicon team with me today. Sitting to the direct right of me is Craig ...
Feline HCM remains a complex, prevalent, and often-devastating disease. While cats can remain asymptomatic for years, progression to CHF or thromboembolism can be sudden. A structured approach to ...
CryoTherapeutics partners with SpectraWAVE and CRF to Launch ICECAP: A First-of-its-Kind Clinical Study Targeting Non-Obstructive High-Risk Coronary Plaques with Cryotherapy and Advanced Intravascular ...
Mavacamten treatment in oHCM patients led to new atrial fibrillation/flutter and heart failure, with frequent acute care episodes within months. Nearly half of the patients required dose adjustments, ...
Extra scrutiny is warranted to identify the underlying causes of chest pain in patients with nonobstructive coronary disease (NOCA), urges a new scientific statement from the American Heart ...
A new study found people with untreated obstructive sleep apnea could have an increased risk of developing Parkinson’s disease. Researchers studied medical records for more than 11 million military ...
At UKG Aspire 2025, UKG announced its Workforce Intelligence Hub, designed to consolidate workforce data across HR, pay, and workforce management, and combine it with external benchmarks and other ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback